---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-274580"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:44:03.122393+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DBV reports positive 2-year OLE results for Viaskin Peanut in toddlers; 81.3% reach 1,000 mg eliciting dose

## Summary
- After 24 months, 81.3% of subjects reached eliciting dose >=1,000 mg peanut protein vs 64.2% at 12 months.
- 55.9% completed the 3,444 mg DBPCFC without meeting stopping criteria, up from 30.7% at 12 months.
- No treatment-related anaphylaxis or serious TEAEs in second year; local application site reactions decreased.
- Placebo crossover group (12 months VP250) showed 62.7% reaching >=1,000 mg ED; single anaphylaxis event.
- Results to be presented at ACAAI Nov 11; investor call/webcast Nov 9 at 5pm ET.

## SEC filing metadata
- accession: 0001193125-23-274580
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312523274580/0001193125-23-274580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312523274580/d286743d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-274580
- JSON: https://secwatch.observer/filing/0001193125-23-274580.json
- Plain text: https://secwatch.observer/filing/0001193125-23-274580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.